Literature DB >> 24186320

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.

Xenofon Papanikolaou1, Christoph J Heuck, Bart Barlogie.   

Abstract

Keywords:  chemotherapy; metronomic therapy; multiple myeloma; relapsed refractory

Mesh：

Year:  2013        PMID： 24186320      PMCID： PMC3815192          DOI： 10.3324/haematol.2013.098939

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Redefining the target: chemotherapeutics as antiangiogenics.

Authors:  K D Miller; C J Sweeney; G W Sledge
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

Review 2.  The anti-angiogenic basis of metronomic chemotherapy.

Authors:  Robert S Kerbel; Barton A Kamen
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Authors:  Laura Rosiñol; Ramón García-Sanz; Juan José Lahuerta; Miguel Hernández-García; Miquel Granell; Javier de la Rubia; Albert Oriol; Belén Hernández-Ruiz; Consuelo Rayón; Isabel Navarro; Juan Carlos García-Ruiz; Joan Besalduch; Santiago Gardella; Javier López Jiménez; Joaquín Díaz-Mediavilla; Adrián Alegre; Jesús San Miguel; Joan Bladé
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.

Authors:  Rok Humar; Fabrice N Kiefer; Hartmut Berns; Thérèse J Resink; Edouard J Battegay
Journal:  FASEB J       Date:  2002-06       Impact factor: 5.191

6.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

Review 7.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Authors:  Antje Hoering; John Crowley; John D Shaughnessy; Klaus Hollmig; Yazan Alsayed; Jackie Szymonifka; Sarah Waheed; Bijay Nair; Frits van Rhee; Elias Anaissie; Bart Barlogie
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

9.  Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.

Authors:  Bart Barlogie; Elias Anaissie; Jeffrey Haessler; Fritz van Rhee; Mauricio Pineda-Roman; Klaus Hollmig; Yazan Alsayed; Joshua Epstein; John D Shaughnessy; John Crowley
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

10.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

Authors:  Silvia Dellapasqua; Francesco Bertolini; Vincenzo Bagnardi; Elisabetta Campagnoli; Eloise Scarano; Rosalba Torrisi; Yuval Shaked; Patrizia Mancuso; Aron Goldhirsch; Andrea Rocca; Elisabetta Pietri; Marco Colleoni
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544
View more
  2 in total

1.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

2.  Metronomic chemotherapy in anaplastic thyroid carcinoma: a potentially feasible alternative to therapeutic nihilism.

Authors:  Swaroop Revannasiddaiah; Irappa Madabhavi; Anita Bodh; Priyanka Thakur; Mukesh Sharma
Journal:  Indian J Palliat Care       Date:  2015 May-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.